这篇文章不错，转发给_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

翁莎
2021-11-12

这篇文章不错，转发给大家看

Ocugen合作伙伴新冠疫苗对重症有效性为93.4%

医学杂志《柳叶刀》公布的数据显示，Ocugen(OCGN.US)合作伙伴Bharat Biotech的新冠疫苗COVAXIN在3期临床试验中对重症的有效性为93.4%。

Ocugen合作伙伴新冠疫苗对重症有效性为93.4%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":879269997,"tweetId":"879269997","gmtCreate":1636728703248,"gmtModify":1636728703248,"author":{"id":3473998581548805,"idStr":"3473998581548805","authorId":3473998581548805,"authorIdStr":"3473998581548805","name":"翁莎","avatar":"https://static.tigerbbs.com/0c132a12301b9bb8dd4c0809fa168090","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","htmlText":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","text":"这篇文章不错，转发给大家看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/879269997","repostId":2182095030,"repostType":2,"repost":{"id":"2182095030","pubTimestamp":1636702503,"share":"https://www.laohu8.com/m/news/2182095030?lang=&edition=full","pubTime":"2021-11-12 15:35","market":"us","language":"zh","title":"Ocugen合作伙伴新冠疫苗对重症有效性为93.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2182095030","media":"智通财经网","summary":"医学杂志《柳叶刀》公布的数据显示，Ocugen(OCGN.US)合作伙伴Bharat Biotech的新冠疫苗COVAXIN在3期临床试验中对重症的有效性为93.4%。","content":"<p>智通财经APP获悉，医学杂志《柳叶刀》公布的数据显示，Ocugen合作伙伴Bharat Biotech的新冠疫苗COVAXIN在3期临床试验中对重症的有效性为93.4%。此外，世界卫生组织(WHO)已于本月初批准了该新冠疫苗的紧急使用授权。</p>\n<p>Ocugen表示，该公司计划在美国进行该新冠疫苗的商业化，“由于疫苗接种率仍然明显低于实现群体免疫所需的接种率，因此迫切需要更多的疫苗选择。”该公司于上月表示，已寻求美国食品和药物管理局(FDA)批准美国开展COVAXIN的晚期研究。</p>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen合作伙伴新冠疫苗对重症有效性为93.4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen合作伙伴新冠疫苗对重症有效性为93.4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 15:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/600502.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，医学杂志《柳叶刀》公布的数据显示，Ocugen合作伙伴Bharat Biotech的新冠疫苗COVAXIN在3期临床试验中对重症的有效性为93.4%。此外，世界卫生组织(WHO)已于本月初批准了该新冠疫苗的紧急使用授权。\nOcugen表示，该公司计划在美国进行该新冠疫苗的商业化，“由于疫苗接种率仍然明显低于实现群体免疫所需的接种率，因此迫切需要更多的疫苗选择。”该公司于上月表示...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/600502.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6e474d690ea02c536f0fd4c03fc3ddef","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://www.zhitongcaijing.com/content/detail/600502.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2182095030","content_text":"智通财经APP获悉，医学杂志《柳叶刀》公布的数据显示，Ocugen合作伙伴Bharat Biotech的新冠疫苗COVAXIN在3期临床试验中对重症的有效性为93.4%。此外，世界卫生组织(WHO)已于本月初批准了该新冠疫苗的紧急使用授权。\nOcugen表示，该公司计划在美国进行该新冠疫苗的商业化，“由于疫苗接种率仍然明显低于实现群体免疫所需的接种率，因此迫切需要更多的疫苗选择。”该公司于上月表示，已寻求美国食品和药物管理局(FDA)批准美国开展COVAXIN的晚期研究。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1544,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}